Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-R: Andexanet Alfa for Rivaroxaban Reversal
NCT02220725Phase 3Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- May 2014
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of andexanet alfa in hemorrhage (4 arms), sponsored by Portola Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Anti-fXa Activity at the Nadir at 5 minutes. Started May 2014; status: completed.
02
Drugs
andexanet alfa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02220725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220725.